Avanza Fonder’s Moderna MRNA Stock Holding History

Avanza Fonder’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,504	Closed	-$865K	–	516
2025 Q3	$865K	Hold	33,504	–	–	0.02%	353
2025 Q2	$924K	Hold	33,504	–	–	0.03%	345
2025 Q1	$929K	Hold	33,504	–	–	0.03%	352
2024 Q4	$1.39M	Buy	+33,504	New	+$1.6M	0.04%	309

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Avanza Fonder's MRNA Position: Q4 2025 in Review

Avanza Fonder sold out of Moderna (MRNA) in Q4 2025, closing a stake of 33,504 shares — an estimated $865K sold.

Avanza Fonder first reported a position in MRNA in Q4 2024 and held it in 4 quarters. The position peaked at $1.39M in Q4 2024. 673 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

Avanza Fonder reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
Avanza Fonder sold 33,504 Moderna shares in Q4 2025, an estimated $865K.
Avanza Fonder first reported a position in Moderna in Q4 2024 and held it in 4 quarters.
Avanza Fonder's Moderna position peaked at $1.39M in Q4 2024.
673 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Avanza Fonder's 13F filing for Q4 2025, filed 12 Jan 2026.